产品详情
Targets
Target | Value |
---|---|
AuroraA | ki: 8nM |
AuroraB | ki: 9nM |
VEGFR2 | ki: 44nM |
FLT3 | ki: 44nM |
CDK2/CyclinE | ki: 0.39μM |
CDK9/CyclinT | ki: 0.48μM |
p70S6K | ki: 0.54μM |
Src | ki: 0.82μM |
CDK4/CyclinD | ki: 1.09μM |
LCK | ki: 2.8μM |
CDK1/CyclinB | ki: >10μM |
CDK7/CyclinH | ki: >10μM |
Abl | ki: >10μM |
Akt | ki: >10μM |
CaMKII | ki: >10μM |
CK2 | ki: >10μM |
ERK2 | ki: >10μM |
GSK-3α | ki: >10μM |
GSK-3β | ki: >10μM |
PKA | ki: >10μM |
PKC | ki: >10μM |
SAPK2A(p38α) | ki: >10μM |
PLK1 | ki: >10μM |
In vitro (25°C) | DMSO | Warmed: 24 mg/mL (65.13 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 1% DMSO+30% polyethylene glycol+1% Tween 80 | 28 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 27.14 mL | 135.69 mL | 271.37 mL |
0.5 mM | 5.43 mL | 27.14 mL | 54.27 mL |
1 mM | 2.71 mL | 13.57 mL | 27.14 mL |
5 mM | 0.54 mL | 2.71 mL | 5.43 mL |
*The above data is based on the productmolecular weight 368.5. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A10248 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 368.5 |
Formula | C18H20N6OS |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 693228-63-6 |
Synonyms | CYC-116 |
SMILES | CC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4 |
产品标签
Product Questions
Product Questions
Brivanib (BMS-540215)
Brivanib (BMS-540215)是一种VEGFR-2抑制剂,IC50为25 nM,Ki为26 nM。
Imatinib (Gleevec)
Imatinib (Gleevec)是一种多靶点酪氨酸激酶抑制剂,抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6,0.1和0.1 μM。
Raf265 derivative
Raf265 derivative是Raf265的衍生物,Raf265是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,IC50为5至10μM。
SU 5416 (Semaxinib)
SU 5416 (Semaxinib)是血管内皮生长因子受体(VEGFR)的抑制剂,它还抑制其他酪氨酸激酶KIT,MET,FLT3和RET。
Bibf1120 (Nintedanib)
Bibf1120 (Nintedanib)是一种新型的三联血管激酶抑制剂,可同时抑制三种生长因子受体:VEGFR,PDGF和FGFR。